Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than 50,000 people in Japan. The goal of […] The post Mosliciguat for PH-ILD granted orphan drug status in Japan appeared first on Pu...| Pulmonary Hypertension News – The Web's Daily Resource for PH News
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis of biomarker data from an ongoing Phase 2a clinical trial. “These 6-week interim biomarker data, while early and based on a small subset of participants, continue to […] The post GRI-0621 may reduce scarring in idiopathic pulmonary fibrosis: Trial appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News